Log in
E-mail
Password
Remember
Forgot password ?
Become a member for free
Sign up
Sign up
Settings
Settings
Dynamic quotes 
OFFON

4-Traders Homepage  >  Equities  >  Nyse  >  C R Bard Inc    BCR

C R BARD INC (BCR)
Mes dernières consult.
Most popular
  Report  
SummaryQuotesNewsAnalysisCalendarCompanyFinancialsConsensusRevisions 
News SummaryMost relevantAll newsSector newsTweets

BARD(CR) : Bard Announces Agreement to Acquire Medivance, Inc.

share with twitter share with LinkedIn share with facebook
share via e-mail
0
10/25/2011 | 10:15pm CET

C. R. Bard, Inc. (NYSE: BCR) today announced that it has reached a definitive agreement to acquire Medivance, Inc. for a purchase price of approximately $250 million. The transaction will be structured as a merger subject to the satisfaction of customary conditions, including Hart-Scott-Rodino clearance. Upon completion of the merger, the Medivance organization will become part of Bard Medical division.

Medivance, located in Louisville, Colorado, is the market leader in the field of therapeutic hypothermia. In recent years, accurate manipulation of body temperature to targeted levels has emerged as an effective treatment option for a variety of critically ill patients. The American Heart Association, The American Stroke Association, The Brain Trauma Foundation and various international medical associations have issued therapeutic hypothermia guidelines as the clinical data supporting Targeted Temperature Management? has grown. Medivance's Arctic Sun® family of products provides clinicians with a powerful technology to effectively manage patient temperature in a non-invasive manner.

Timothy M. Ring, chairman and CEO, commented, "With their unique and proprietary technology, Medivance is the market leader in an emerging and growing space. This merger is a great strategic fit for Bard as Medivance's Targeted Temperature Management? product line is synergistic with our critical care sales call point, and their technology efficiently addresses a large unmet need in a market that is growing double digits. This acquisition represents an important building block for our critical care product offering."

Based on the anticipated completion of the merger in the fourth quarter of 2011, Bard expects the dilution impact to be immaterial to earnings per share in 2011.

C. R. Bard, Inc. (www.crbard.com), headquartered in Murray Hill, NJ, is a leading multinational developer, manufacturer and marketer of innovative, life-enhancing medical technologies in the fields of vascular, urology, oncology and surgical specialty products.

This press release may contain forward-looking statements within the meaning of the Private Securities Litigation Reform Act of 1995, which are based on management's current expectations, the accuracy of which is necessarily subject to risks and uncertainties. These statements are not historical in nature and use words such as "anticipate", "estimate", "expect", "project", "intend", "forecast", "plan", "believe", and other words of similar meaning in connection with any discussion of future operating or financial performance. Many factors may cause actual results to differ materially from anticipated results including product developments, sales efforts, income tax matters, the outcomes of contingencies such as legal proceedings, and other economic, business, competitive and regulatory factors. The company undertakes no obligation to update its forward-looking statements. Please refer to the Cautionary Statement Regarding Forward-Looking Information in our June 30, 2011 Form 10-Q for more detailed information about these and other factors that may cause actual results to differ materially from those expressed or implied.

C. R. Bard, Inc.
Investor Relations:
Todd W. Garner, 908-277-8065
Vice President, Investor Relations
or
Media Relations:
Scott T. Lowry, 908-277-8365
Vice President and Treasurer


© Business Wire 2011
share with twitter share with LinkedIn share with facebook
share via e-mail
0
Latest news on C R BARD INC
01/02BECTON DICKINSON AND : BD Completes Bard Acquisition, Creating New Global Health..
AQ
01/01BECTON, DICKINSON AND COMPANY (NYSE : BDX) Files An 8-K Other Events
AQ
2017BARD C R INC /NJ/ : Entry into a Material Definitive Agreement, Termination of a..
AQ
2017C R BARD : BD Completes Bard Acquisition, Creating New Global Health Care Leader
PR
2017BECTON DICKINSON AND : and C. R. Bard; Analysis To Aid Public Comment
AQ
2017C R BARD : BD Statement On MOFCOM Clearance Of Bard Acquisition
PR
2017BECTON DICKINSON AND : FTC Requires Divestiture of Two Medical Device Product Li..
AQ
2017C R BARD : BD Statement On FTC Clearance Of Bard Acquisition
PR
2017C R BARD : Researchers Submit Patent Application, "Implantable Prosthesis for So..
AQ
2017BECTON DICKINSON AND : U.S. Patents Awarded to Inventors in Utah (Dec. 15)
AQ
More news
News from SeekingAlpha
01/23Fundsmith Annual Letter To Shareholders 2017 
01/08Dividend Income Update December 2017 
2017Dividend Champions For January 2018 (Part 1) 
2017Huntington Ingalls set to join S&P 500 
2017FTC conditionally signs off on BD's takeover of Bard 
Financials ($)
Income Statement Evolution
Consensus
 
Mean consensus
Number of Analysts
Average target price -
Spread / Average Target
EPS Revisions
Managers
NameTitle
Timothy M. Ring Chief Executive Officer
Christopher S. Holland Chief Financial Officer & Senior Vice President
John A. DeFord Senior VP-Science, Technology & Clinical Affairs
Patricia G. Christian VP-Quality, Regulatory & Medical Affairs
Patrick D. Roche Vice President-Information Technology Solutions
Sector and Competitors
1st jan.Capitalization (M$)
C R BARD INC0.00%0
MEDTRONIC PLC1.37%112 760
BAXTER INTERNATIONAL2.15%36 139
ZIMMER BIOMET HOLDINGS-2.46%24 394
ALIGN TECHNOLOGY10.87%20 165
HOYA CORPORATION-3.69%19 925